Reviewer's report

Title: Changing Paradigms in Management of metastatic Castration Resistant Prostate Cancer (mCRPC)

Version: 3 Date: 10 June 2014

Reviewer: Satoshi Anai

Reviewer's report:

Discretionary Revisions

General comments:

Authors clearly summarized that targeting androgen receptor (AR) has been a key to manage metastatic castrate resistant prostate cancer (mCRPC) in this manuscript. This review provides us enough information about phenomenon of the castration resistant state and the new strategy for treatment of mCRPC. Once authors revise the points which the reviewers pointed, this manuscript should be accepted by this journal.

Title/ Key words: appropriate

Abstract:
The abstract is good structured and gives appropriate information about this manuscript.

Introduction:
- Authors might have better mention what LhRH antagonist such as degarelix acetate is for medical castration.

New Approved Hormonal Treatments:
- Although toxicity profile of enzalutamide were described in the different section, that of abiraterone were described in the same section. The fashion of writing might have better be the same.

Conclusion:
- Well written conclusion section.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:

'I declare that I have no competing interests'